With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.
SIK inhibitor II-1[00389] To a solution of 1-(6-chloropyrimidin-4-yl)-N-(2,6-dimethylphenyl)-1H- imidazol-2-amine (100 mg, 0.33 mmol) and 4-(4- ethylpiperazin-1-yl)aniline (68 mg, 0.33 mmol) in 2-butanol (1 mL) was added trifluoroacetic acid (TFA, 0.1 mL). The resulting mixture was stirred at 120 C for 4 h, concentrated, and diluted with dimethyl sulfoxide (6 mL). The resulting mixture was purified with preparative HPLC to afford 6-(2-((2,6- dimethylphenyl)amino)-1H-imidazol-1-yl)-N-(4-(4- ethylpiperazin-1-yl)phenyl)pyrimidin-4- amine TFA salt (78 mg, 41% yield) as an off-white solid. Rt = 1.93 min;1H NMR (600 MHz; DMSO-d6) 10.71 (br, 1H), 10.02 (s, 1H), 9.97 (br, 1H), 8.54 (s, 1H), 7.65 (s, 1H), 7.48 (d, J = 6.6 Hz, 2H), 7.20 (m, 4H), 7.10 (s, 1H), 7.01 (d, J = 9.0 Hz, 2H), 6.95 (s, 1H), 3.78 (m, 2H), 3.56 (m, 2H), 3.17 (m, 2H), 3.09 (m, 2H), 2.94 (m, 2H), 2.18 (s, 6H), 1.23 (m, 3H) ppm; MS m/z: 469.46 [M+1].
115619-01-7, The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; DANA-FARBER CANCER INSTITUTE, INC.; THE BROAD INSTITUTE, INC.; THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; SHAMJI, Alykhan; SUNDBERG, Thomas; GRAY, Nathanael; XAVIER, Ramnik; SCHREIBER, Stuart, L.; CHOI, Hwan, Geun; LIANG, Yanke; (315 pag.)WO2016/23014; (2016); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics